Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Preoperative dexamethasone palmitate to prevent nausea and vomiting after craniotomy

Official title: Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy

Run by Beijing Tiantan Hospital · NCT06988124 · Data updated 2026-11-12

This will try whether a long-acting form of dexamethasone given before elective craniotomy reduces nausea and vomiting within 24 hours in adults aged 18–65.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment500 (estimated)
SponsorBeijing Tiantan Hospital
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedJune 25, 2025
Main results expectedMay 1, 2027
Study endsJune 1, 2027
Registry record updatedSeptember 23, 2025
Trial IDNCT06988124 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–65 scheduled for elective craniotomy under general anesthesia who can give informed consent and do not have recent systemic glucocorticoid use or major contraindicating illnesses.

Probably not a fit

Patients with known dexamethasone allergy, recent systemic glucocorticoid use, uncontrolled diabetes, severe heart/liver/kidney disease, systemic rheumatic disease, pregnancy, breastfeeding, cognitive impairment, or severe mental illness are excluded and unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Dexamethasone palmitate, a lipid-formulated longer-acting corticosteroid, is being compared with standard dexamethasone given before elective craniotomy. Adult patients aged 18–65 undergoing general anesthesia will receive one of the two preoperative treatments and be followed for postoperative nausea and vomiting and adverse events. The main outcome is PONV within the first 24 hours after surgery, with additional data on rescue antiemetic use and safety. Patients with recent systemic steroids, severe organ dysfunction, uncontrolled diabetes, pregnancy or steroid allergy are excluded.

Why it matters

Potential benefit: If successful, this could reduce early postoperative nausea and vomiting after craniotomy and provide longer-lasting antiemetic protection with fewer steroid-related side effects.

How similar studies have gone: Standard dexamethasone is commonly used and shows benefit for PONV prevention, but dexamethasone palmitate has limited published data in this surgical context and remains less tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 18 to 65 years;
* Providing written informed consent;
* Perform elective craniotomy undergoing general anesthesia.

Exclusion Criteria:

* Known to be allergic to dexamethasone;
* Any systemic glucocorticoids within 3 months before trial entry;
* History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
* Cognitive impairment or severe mental illness;
* Uncontrolled diabetes or infectious diseases;
* Pregnancy or breastfeeding.

Where it's running

  • Fang Luo
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.